RTT Molecular Dx USA, Inc./RTT Molecular Dx Canda, Inc.

RTT MolecularDx, Inc. Has a succesful CVS May 6-9 2018 West Palm Beach, FL. The company launches CoreCONCEPTS a "soup to nuts" diagnostic sequencing solution including MST (Mutation Screening Test) and CoreFLEX confirmatory testing via GeneTHINK CoreSEQ (former TRUGENE) IVD Kits and the single multi use platform TSASS (former TRUGENE Long Read Sequencing Tower). Screening to solid state sequencing using the trusted chemistry and improved reporting algorithms of Siemens former TRUGENE and OpeneGene System. One (1) system two (2) different technologies combined with fully integrated reporting make this proven > 20 year veteran diagnostic platform a legacy.

RTTMDx begins FDA regulatory documentation for three different technologies.

Hepatitis C Virus (HCV) drug resistance has been made a whole lot less confusing with GeneTHINK and TSASS platform

PR NEWS WIRE RELEASE 4:52 PM RTT MolecularDX Launches HIV-1, HBV and HCV Drug Resistance and GeneTHINK Fully Integrated System First-of-its-kind drug resistance screening and sequencing kit enables more efficacious and cost effective treatment of virus JENSEN BEACH, Fla., April 11, 2017 /PRNewswire/ -- RTT MolecularDX USA, Inc. (RTTMDx) a provider of infectious disease Drug Resistance (DR) genotyping tests, announced today the pre-market launch of its Human Immunodeficiency ...Continue reading

RTT Molecular Dx, Inc. to license molecular testing technologies for diagnostic genotyping.